Top

Journal of Cancer Research and Clinical Oncology

Published in:

01-07-2015 | Original Article – Clinical Oncology

A tumor-specific microRNA signature predicts survival in clear cell renal cell carcinoma

Authors: Yu-Zheng Ge, Ran Wu, Hui Xin, Meng Zhu, Tian-Ze Lu, Hao Liu, Zheng Xu, Peng Yu, You-Cai Zhao, Ming-Hao Li, Zhi-Kai Hu, Yan Zhao, Bing Zhong, Xiao Xu, Liu-Hua Zhou, Lu-Wei Xu, Jian-Ping Wu, Wen-Cheng Li, Jia-Geng Zhu, Rui-Peng Jia

Published in: Journal of Cancer Research and Clinical Oncology | Issue 7/2015

Abstract

Purpose

Clear cell renal cell carcinoma (ccRCC) is the most common subtype of kidney cancers in adults, and microRNAs (miRNAs) differentially expressed in ccRCC tumors have been identified and proposed to predict prognosis. In the present study, we comprehensively analyzed the genome-wide miRNA expression profiles in ccRCC, with the aim to generate a tumor-specific miRNA signature of prognostic values.

Methods

The miRNA profiles in tumor and the adjacent normal tissue were analyzed, and the association of the differentially expressed miRNAs with patient survival was examined with univariate Cox regression analysis. Finally, a tumor-specific miRNA signature was generated and examined with Kaplan–Meier survival, univariate, and multivariate Cox regression analyses.

Results

A total of 147 miRNAs were found differentially expressed between tumor and matched non-tumor tissues from 58 ccRCC patients. The prognostic values of these differentially expressed miRNAs were subsequently analyzed in the 411 ccRCC patients, and 22 miRNAs were found significantly correlated with patient survival. Finally, a tumor-specific miRNA signature of 22 miRNAs was generated and validated as an independent prognostic parameter.

Conclusions

A tumor-specific miRNA signature consisting of 22 miRNAs was identified and validated as an independent prognostic factor, which could serve as a novel biomarker for ccRCC prognostication and help in predicting treatment outcome.

Available only for authorised users

Baek D, Villen J, Shin C, Camargo FD, Gygi SP, Bartel DP (2008) The impact of microRNAs on protein output. Nature 455:64–71. doi:10.1038/nature07242 CrossRefPubMedCentralPubMed

Bartel DP (2004) MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116:281–297CrossRefPubMed

Calin GA, Croce CM (2006) MicroRNA signatures in human cancers. Nat Rev Cancer 6:857–866. doi:10.1038/nrc1997 CrossRefPubMed

Cancer Genome Atlas Research N (2013) Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature 499:43–49. doi:10.1038/nature12222

Catto JW et al (2011) MicroRNA in prostate, bladder, and kidney cancer: a systematic review. Eur Urol 59:671–681. doi:10.1016/j.eururo.2011.01.044 CrossRefPubMed

Chen X et al (2014) miR-129-3p, as a diagnostic and prognostic biomarker for renal cell carcinoma, attenuates cell migration and invasion via downregulating multiple metastasis-related genes. J Cancer Res Clin Oncol 140:1295–1304. doi:10.1007/s00432-014-1690-7 CrossRefPubMed

Ferlay J et al (2013) Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer 49:1374–1403. doi:10.1016/j.ejca.2012.12.027 CrossRefPubMed

Fritz HK, Lindgren D, Ljungberg B, Axelson H, Dahlback B (2014) The miR(21/10b) ratio as a prognostic marker in clear cell renal cell carcinoma. Eur J Cancer 50:1758–1765. doi:10.1016/j.ejca.2014.03.281 CrossRefPubMed

Gowrishankar B et al (2014) MicroRNA expression signatures of stage, grade, and progression in clear cell RCC. Cancer Biol Ther 15:329–341. doi:10.4161/cbt.27314 CrossRefPubMedCentralPubMed

Gulati S et al (2014) Systematic evaluation of the prognostic impact and intratumour heterogeneity of clear cell renal cell carcinoma biomarkers. Eur Urol. doi:10.1016/j.eururo.2014.06.053 PubMedCentralPubMed

Hidaka H et al (2012) Tumor suppressive microRNA-1285 regulates novel molecular targets: aberrant expression and functional significance in renal cell carcinoma. Oncotarget 3:44–57

Hildebrandt MA et al (2010) Hsa-miR-9 methylation status is associated with cancer development and metastatic recurrence in patients with clear cell renal cell carcinoma. Oncogene 29:5724–5728. doi:10.1038/onc.2010.305 CrossRefPubMed

Iorio MV, Croce CM (2012) microRNA involvement in human cancer. Carcinogenesis 33:1126–1133. doi:10.1093/carcin/bgs140 CrossRefPubMedCentralPubMed

Jansson MD, Lund AH (2012) MicroRNA and cancer. Mol Oncol 6:590–610. doi:10.1016/j.molonc.2012.09.006 CrossRefPubMed

Juan D et al (2010) Identification of a microRNA panel for clear-cell kidney cancer. Urology 75:835–841. doi:10.1016/j.urology.2009.10.033 CrossRefPubMed

Kozomara A, Griffiths-Jones S (2014) miRBase: annotating high confidence microRNAs using deep sequencing data. Nucleic Acids Res 42:D68–D73. doi:10.1093/nar/gkt1181 CrossRefPubMedCentralPubMed

Lewis BP, Burge CB, Bartel DP (2005) Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 120:15–20. doi:10.1016/j.cell.2004.12.035

Liu H et al (2010a) Identifying mRNA targets of microRNA dysregulated in cancer: with application to clear cell renal cell carcinoma. BMC Syst Biol 4:51. doi:10.1186/1752-0509-4-51 CrossRefPubMedCentralPubMed

Liu W et al (2010b) miR-23b targets proline oxidase, a novel tumor suppressor protein in renal cancer. Oncogene 29:4914–4924. doi:10.1038/onc.2010.237 CrossRefPubMedCentralPubMed

Liu N et al (2012) Prognostic value of a microRNA signature in nasopharyngeal carcinoma: a microRNA expression analysis. Lancet Oncol 13:633–641. doi:10.1016/S1470-2045(12)70102-X CrossRefPubMed

Liu C et al (2014) microRNA-548l is involved in the migration and invasion of non-small cell lung cancer by targeting the AKT1 signaling pathway. J Cancer Res Clin Oncol. doi:10.1007/s00432-014-1836-7

Ljungberg B et al (2010) EAU guidelines on renal cell carcinoma: the 2010 update. Eur Urol 58:398–406. doi:10.1016/j.eururo.2010.06.032 CrossRefPubMed

Lopez-Beltran A, Scarpelli M, Montironi R, Kirkali Z (2006) 2004 WHO classification of the renal tumors of the adults. Eur Urol 49:798–805. doi:10.1016/j.eururo.2005.11.035 CrossRefPubMed

Lopez-Beltran A, Carrasco JC, Cheng L, Scarpelli M, Kirkali Z, Montironi R (2009) 2009 Update on the classification of renal epithelial tumors in adults. Int J Urol 16:432–443. doi:10.1111/j.1442-2042.2009.02302.x

Lorenzen JM, Thum T (2012) Circulating and urinary microRNAs in kidney disease. Clin J Am Soc Nephrol 7:1528–1533. doi:10.2215/CJN.01170212 CrossRefPubMed

Lossos IS, Czerwinski DK, Alizadeh AA, Wechser MA, Tibshirani R, Botstein D, Levy R (2004) Prediction of survival in diffuse large-B-cell lymphoma based on the expression of six genes. New Engl J Med 350:1828–1837. doi:10.1056/NEJMoa032520 CrossRefPubMed

Maher ER (2013) Genomics and epigenomics of renal cell carcinoma. Semin Cancer Biol 23:10–17. doi:10.1016/j.semcancer.2012.06.003 CrossRefPubMed

Mlcochova H, Hezova R, Stanik M, Slaby O (2014) Urine microRNAs as potential noninvasive biomarkers in urologic cancers. Urol Oncol 32(41):e41–e49. doi:10.1016/j.urolonc.2013.04.011

Osanto S, Qin Y, Buermans HP, Berkers J, Lerut E, Goeman JJ, van Poppel H (2012) Genome-wide microRNA expression analysis of clear cell renal cell carcinoma by next generation deep sequencing. PloS One 7:e38298. doi:10.1371/journal.pone.0038298 CrossRefPubMedCentralPubMed

Park I et al (2014) Active surveillance for metastatic or recurrent renal cell carcinoma. J Cancer Res Clin Oncol 140:1421–1428. doi:10.1007/s00432-014-1680-9 CrossRefPubMed

Reis LO, Pereira TC, Lopes-Cendes I, Ferreira U (2010) MicroRNAs: a new paradigm on molecular urological oncology. Urology 76:521–527. doi:10.1016/j.urology.2010.03.012

Sandoval J, Esteller M (2012) Cancer epigenomics: beyond genomics. Curr Opin Genet Dev 22:50–55. doi:10.1016/j.gde.2012.02.008 CrossRefPubMed

Selbach M, Schwanhausser B, Thierfelder N, Fang Z, Khanin R, Rajewsky N (2008) Widespread changes in protein synthesis induced by microRNAs. Nature 455:58–63. doi:10.1038/nature07228 CrossRefPubMed

Shuch B et al (2014) Understanding pathologic variants of renal cell carcinoma: distilling therapeutic opportunities from biologic complexity. Eur Urol. doi:10.1016/j.eururo.2014.04.029 PubMed

Siegel R, Ma J, Zou Z, Jemal A (2014) Cancer statistics, 2014 CA. Cancer J Clin 64:9–29. doi:10.3322/caac.21208 CrossRef

Silva-Santos RM et al (2013) MicroRNA profile: a promising ancillary tool for accurate renal cell tumour diagnosis. Br J Cancer 109:2646–2653. doi:10.1038/bjc.2013.552 CrossRefPubMedCentralPubMed

White NM et al (2011) miRNA profiling for clear cell renal cell carcinoma: biomarker discovery and identification of potential controls and consequences of miRNA dysregulation. J Urol 186:1077–1083. doi:10.1016/j.juro.2011.04.110 CrossRefPubMed

Wu X et al (2012) Identification of a 4-microRNA signature for clear cell renal cell carcinoma metastasis and prognosis. PLoS ONE 7:e35661. doi:10.1371/journal.pone.0035661 CrossRefPubMedCentralPubMed

Yates LA, Norbury CJ, Gilbert RJ (2013) The long and short of microRNA. Cell 153:516–519. doi:10.1016/j.cell.2013.04.003 CrossRefPubMed

Yi Z, Fu Y, Zhao S, Zhang X, Ma C (2010) Differential expression of miRNA patterns in renal cell carcinoma and nontumorous tissues. J Cancer Res Clin Oncol 136:855–862. doi:10.1007/s00432-009-0726-x CrossRefPubMed

Yu SL et al (2008) MicroRNA signature predicts survival and relapse in lung cancer. Cancer Cell 13:48–57. doi:10.1016/j.ccr.2007.12.008 CrossRefPubMed

Zhao Y, Simon R (2008) BRB-ArrayTools data archive for human cancer gene expression: a unique and efficient data sharing resource. Cancer Inf 6:9–15

Title: A tumor-specific microRNA signature predicts survival in clear cell renal cell carcinoma
Authors: Yu-Zheng Ge
Ran Wu
Hui Xin
Meng Zhu
Tian-Ze Lu
Hao Liu
Zheng Xu
Peng Yu
You-Cai Zhao
Ming-Hao Li
Zhi-Kai Hu
Yan Zhao
Bing Zhong
Xiao Xu
Liu-Hua Zhou
Lu-Wei Xu
Jian-Ping Wu
Wen-Cheng Li
Jia-Geng Zhu
Rui-Peng Jia
Publication date: 01-07-2015
Publisher: Springer Berlin Heidelberg
Published in: Journal of Cancer Research and Clinical Oncology / Issue 7/2015
Print ISSN: 0171-5216
Electronic ISSN: 1432-1335
DOI: https://doi.org/10.1007/s00432-015-1927-0

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

A tumor-specific microRNA signature predicts survival in clear cell renal cell carcinoma

Abstract

Purpose

Methods

Results

Conclusions

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 7/2015

Inhibition of S6K1 enhances dichloroacetate-induced cell death

Visceral and subcutaneous fat as new independent predictive factors of survival in locally advanced gastric carcinoma patients treated with neo-adjuvant chemotherapy

Anti-LeY antibody enhances therapeutic efficacy of celecoxib against gastric cancer by downregulation of MAPKs/COX-2 signaling pathway: correlation with clinical study

Cytochrome P450 1B1 (CYP1B1) polymorphisms are associated with clinical outcome of docetaxel in non-small cell lung cancer (NSCLC) patients

FIB-4 index for assessing the prognosis of hepatocellular carcinoma in patients with Child-Pugh class A liver function

Meningiomas after cranial radiotherapy for childhood cancer: a single institution experience

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page